[1]汪梦园,袁军,张慧芝.四种前列腺素类药物的降眼压疗效和耐受性对比研究[J].眼科新进展,2019,39(10):944-947.[doi:10.13389/j.cnki.rao.2019.0215]
　WANG Meng-Yuan,YUAN Jun,ZHANG Hui-Zhi.Efficacy and tolerance of four prostaglandins in reducing intraocular pressure[J].Recent Advances in Ophthalmology,2019,39(10):944-947.[doi:10.13389/j.cnki.rao.2019.0215]
点击复制

四种前列腺素类药物的降眼压疗效和耐受性对比研究/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年10期
页码:
944-947
栏目:
应用研究
出版日期:
2019-10-05

文章信息/Info

Title:
Efficacy and tolerance of four prostaglandins in reducing intraocular pressure
作者:
汪梦园; 袁军; 张慧芝
450006　河南省郑州市，郑州市第二人民医院（汪梦园，张慧芝）；450006　河南省郑州市，郑州市第二人民医院眼科（袁军）
Author(s):
WANG Meng-Yuan; YUAN Jun; ZHANG Hui-Zhi
Second People’s Hospital of Zhengzhou(WANG Meng-Yuan,ZHANG Hui-Zhi),Zhengzhou 450006，Henan Province,China;Department of Ophthalmology,the Second People’s Hospital of Zhengzhou(YUAN Jun)，Zhengzhou 450006，Henan Province,China
关键词:
前列腺素类药物; 原发性开角型青光眼; 眼压; 眼表疾病指数评分
Keywords:
prostaglandins; primary open-angle glaucoma; intraocular pressure; ocular surface disease index
分类号:
R775
DOI:
10.13389/j.cnki.rao.2019.0215
文献标志码:
A
摘要:
目的　探讨四种前列腺素类药物治疗原发性开角型青光眼（primary open-angle glaucoma，POAG）的疗效和耐受性差异。方法　采用随机平行试验，64例(128眼)POAG患者随机分成4组，分别使用贝美前列素(贝美前列素组)、拉坦前列素（拉坦前列素组）、曲伏前列素（曲伏前列素组）和他氟前列素（他氟前列素组）滴眼液治疗，观察并比较4组患者用药前和用药后1个月、3个月和6个月的眼压、眼部检查和眼表疾病指数（ocular surface disease index，OSDI）评分。结果　贝美前列素组用药前眼压为（26.1±6.2）mmHg（1 kPa=7.5 mmHg），用药后1个月、3个月和6个月眼压分别为（17.1±3.4）mmHg、（15.6±4.2）mmHg、（15.5±2.9）mmHg，与用药前比较，差异均有统计学意义（t=17.408、13.016、12.352，均为P＜0.001）。拉坦前列素组用药前眼压为（24.7±2.4）mmHg，用药后1个月、3个月和6个月眼压分别为（16.3±3.0）mmHg、（17.0±3.8）mmHg、（17.4±2.6）mmHg，与用药前比较，差异均有统计学意义（t=12.238、13.365、16.140，均为P＜0.001）。曲伏前列素组用药前眼压为（24.4±1.9）mmHg，用药后1个月、3个月和6个月眼压分别为（16.3±2.0）mmHg、（17.4±1.3）mmHg、（14.9±1.1）mmHg，与用药前比较，差异均有统计学意义（t=12.109、14.451、11.732，均为P＜0.001）。他氟前列素组用药前眼压为（25.2±2.3）mmHg，用药后1个月、3个月和6个月眼压分别为（17.2±3.1）mmHg、（17.0±2.1）mmHg、（18.1±2.4）mmHg，与用药前比较，差异均有统计学意义（t=10.540、16.129、14.006，均为P＜0.001）。拉坦前列素组患者睫毛增长和虹膜变色的发生率最高，4组患者的结膜充血和角膜炎的发生率相似。用药6个月后患者的OSDI评分贝美前列素组（21.8±11.1）分、拉坦前列素组（32.1±24.1）分、曲伏前列素组（10.7±5.7）分、他氟前列素组（25.6±6.3）分，曲伏前列素组患者的OSDI评分显著低于其他3组，差异均有统计学意义（均为P＜0.05）。结论　四种前列腺素类药物均能显著降低POAG患者眼压，曲伏前列素耐受性较好，拉坦前列素的耐受性最差。
Abstract:
Objective　To evaluate the differences of efficacy and tolerance of 4 prostaglandins in patients with primary open-angle glaucoma (POAG).Methods　A randomized parallel experiment was conducted in 64 patients with POAG,and these patients were respectively treated with bimatoprost (bimatoprost group),latanoprost (latanoprost group),travoprost (travoprost group),and tafluprost (tafluprost group).Then,the intraocular pressure (IOP),ocular examination and ocular surface disease index (OSDI) score were detected and compared of the 4 groups before treatment,and after treatment for 1 month,3 months and 6 months.Results　For patients in group of bimatoprost,the IOP was (26.1±6.2)mmHg (1 kPa=7.5 mmHg) before treatment,and the IOP was (17.1±3.4)mmHg,(15.6±4.2)mmHg,(15.5±2.9) mmHg after treatment for 1 month,3 months and 6 months,respectively,and the difference was statistically significant compared with that before treatment (t=17.408,13.016,12.352,all P＜0.001).For patients in the latanoprost group,the IOP was (24.7±2.4)mmHg before treatment,and the IOP was (16.3±3.0) mmHg,(17.0±3.8)mmHg,(17.4±2.6)mmHg after treatment for 1 month,3 months and 6 months,respectively,and the difference was statistically significant compared with that before treatment (t=12.238,13.365,16.140,all P＜0.001).For patients in the travoprost group,the IOP was (24.4±1.9)mmHg before treatment,and the IOP was (16.3±2.0)mmHg,(17.4±1.3)mmHg,(14.9±1.1)mmHg after treatment for 1 month,3 months and 6 months respectively,and the difference was statistically significant compared with that before treatment (t=12.109,14.451,11.732,all P＜0.001).For patients in the tafluprost group,the IOP was (25.2±2.3)mmHg before treatment,and the IOP was (17.2±3.1)mmHg,(17.0±2.1)mmHg and (18.1±2.4)mmHg after treatment for 1 month,3 months and 6 months,respectively,and the difference was statistically significant compared with that before treatment (t=10.540,16.129,14.006,all P＜0.001).The incidence of eyelash growth and iris discoloration were highest in the latanoprost group,and the incidence of conjunctival congestion and keratitis was similar in the four groups.After 6 months of treatment,the OSDI was 21.8±11.1,32.1±24.1,10.7±5.7 and 25.6±6.3 for patients in the bimatoprost group,latanoprost group,travoprost group and tafluprost group,and the OSDI for patients in travoprost group was significantly lower than that in the other three groups,and the difference was statistically significant (all P<0.05).Conclusion　All the four prostaglandins can significantly reduce IOP in POAG patients,and the tolerance of travoprost is the best and that of latanoprost is the worst among the four prostaglandins.

参考文献/References:

［1］　Chinese Ophthalmological Society Glaucoma group.Expert consensus on diagnosis and treatment of primary glaucoma in China(2014)［J］.Chin J Ophthalmol,2014,50(5):382-383.
中华医学会眼科学分会青光眼学组.我国原发性青光眼诊断和治疗专家共识(2014)［J］.中华眼科杂志,2014,50(5):382-383.
［2］　LI W N,LI C,LI X X,WEI R L.Clinical investigation of topical medication adherence of glaucoma patients［J］.Chin J Pract Ophthalmol,2013,31(9):1112-1115.
李维娜,李超,李学喜,魏锐利.青光眼患者局部用药依从性调查分析［J］.中国实用眼科杂志,2013,31(9):1112-1115.
［3］　CUI X H,ZHOU X D,XU J J,LE Q H,XIANG J,ZHU W Q,et al.Corneal morphology and sensitivity changes induced by the long-term application of topical prostaglandin analogs［J］.Chin J Optom Ophthalmol Vis Sci,2013,15(6):365-369.
崔心瀚,周晓东,徐建江,乐琦骅,项俊,朱文卿，等.长期使用前列腺素类滴眼液对角膜结构与知觉的影响［J］.中华眼视光学与视觉科学杂志,2013,15(6):365-369.
［4］　DONG Z Z,GAN Y F,ZHANG Y N,ZHENG H H.The efficacy and safety of Tafluprost as a therapy for patients with primary open angle glaucoma［J］.Rec Adv Ophthalmol,2018,38(9):856-860.
董志章,甘一峰,张易南,郑海华.他氟前列素治疗开角型青光眼的疗效观察［J］.眼科新进展,2018,38(9):856-860.
［5］　SONG Y,ZHAO X L.Analysis the factors of individual differences in drug response of prostaglandins in reducing ocular hypotension［J］.Chin J Clin Pharmacol，2016,32(11):1046-1048.
宋尧,赵秀丽.前列腺素类药物降眼压疗效个体差异的影响因素分析［J］.中国临床药理学杂志,2016,32(11):1046-1048.
［6］　LIN C,YANG M M,ZHENG Q.Development and evaluation of Chinese version questionaires of ocular surface disease index［J］.Rec Adv Ophthalmol,2013，33(1):38-40.
林晨,杨敏敏,郑虔.眼表疾病指数量表中文版的研制和性能评价［J］.眼科新进展,2013,33(1):38-40.
［7］　GE J,LI X X,SUN X H,HE X G,ZHANG H.Randomized parallel group study of 0.001 5％tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension(comparison with 0.005％latanoprost ophthalmic solution)［J］.Chin J Ophthalmol，2015,51(2):95-102.
葛坚,黎晓新,孙兴怀,贺翔鸽,张虹.0.001 5%他氟前列素滴眼液与0.005%拉坦前列素滴眼液治疗原发性开角型青光眼和高眼压症的多中心随机单盲平行对照试验［J］.中华眼科杂志,2015,51(2):95-102.
［8］　RANNO S,SACCHI M,BRANCATO C,GILARDI D,LEMBO A,NUCCI P.A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients［J］.Sci World J,2012,2012：804730.
［9］　LIN L,ZHAO Y J,CHEW P T,SNG C C,WONG H T,YIP L W,et al.Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension［J］.Ann Pharmacother,2014,48(12):1585-1593.
［10］　HOMMER A,KIMMICH F.Switching patients from preserved prostaglandin-analog monotherapy to preservativefree tafluprost［J］.Clin Ophthalmol,2011,5（4）:623-631.
［11］　CHEN X,LIU M X.Progress in research and application of preservatives in ophthalmic medications［J］.Tianjin Pharm,2013,25(5):54-59.
陈曦,刘美欣.眼用制剂中防腐剂的研究应用进展［J］.天津药学,2013,25(5):54-59.
［12］　YAN X M.Be aware of toxicity of eye drops to ocular surface［J］.Chin J Ophthalmol,2005,41(5):387-389.
晏晓明.关注滴眼剂的眼表毒性［J］.中华眼科杂志,2005,41(5):387-389.
［13］　ZHU Y.Effects of different preservatives in topical medications on glaucoma patients with dry eye［J］.Chin J Ophthalmol Otorhinolaryngol,2016,16(6):402-405.
朱研.局部药物中不同防腐剂对青光眼患者干眼的影响差异［J］.中国眼耳鼻喉科杂志,2016,16(6):402-405.
［14］　KIM J H,KIM E J,KIM Y H,KIM Y I,LEE S H,JUNG J C,et al.In vivo effects of preservative-free and preserved prostaglandin analogs:mouse ocular surface study［J］.Korean J Ophthalmol,2015,29(4):270-279.

相似文献/References:

[1]陈慧 胡义珍 柯晓云 陈晓虹.睾酮诱导牛眼小梁细胞组织型谷氨酰胺转移酶的表达[J].眼科新进展,2012,32(11):000.
[2]董敬民 张效房 马跃伟 王卫群 孔令训.曲伏前列素治疗原发性开角型青光眼的临床研究[J].眼科新进展,2012,32(12):000.
[3]唐浩英 王璟 卢敏.细胞外钙离子内流上调原发性开角型青光眼患者小梁网细胞Copine1表达的研究[J].眼科新进展,2013,33(8):000.
[4]鲍炯琳 林文雄 曾泳辉 李青 孙丽 王文娟 罗焕然 臧晶.真空小梁成形术治疗原发性开角型青光眼[J].眼科新进展,2012,32(8):000.
[5]徐静 李雪 胡琦 杨帆 吴琼 王珂萌.超高度近视眼屈光力及眼轴影响因素分析[J].眼科新进展,2012,32(10):000.
[6]谢瞻 袁志兰.不同手术方式对POAG患者情绪及生存质量影响的比较[J].眼科新进展,2013,33(5):000.
[7]陆炯 孟逸芳 陶建军 邢茜 顾正.光学相干断层扫描在检测原发性开角型青光眼早期视网膜神经纤维层厚度变化中的应用[J].眼科新进展,2013,33(11):000.
[8]周晓芳,付汛安,李双.超声乳化白内障吸出联合ExPRESS青光眼引流器植入术治疗合并白内障的原发性开角型青光眼[J].眼科新进展,2014,34(6):554.[doi:10.13389/j.cnki.rao.2014.0151]
[9]张敏,王强,王康. 糖基化终末产物对体外培养牛眼小梁细胞氧化应激及凋亡的影响[J].眼科新进展,2014,34(7):640.[doi:10.13389/j.cnki.rao.2014.0175]
[10]叶汉元,曾云,李鸿翎.EX-PRESS青光眼引流器植入术治疗原发性开角型青光眼[J].眼科新进展,2015,35(1):059.[doi:10.13389/j.cnki.rao.2015.0017]
　YE Han-Yuan,ZENG Yun,LI Hong-Ling.EX-PRESS glaucoma filtration device implantation for primary open angle glaucoma[J].Recent Advances in Ophthalmology,2015,35(10):059.[doi:10.13389/j.cnki.rao.2015.0017]

备注/Memo

备注/Memo:
郑州市科技攻关项目（编号：141PPTGG340）
更新日期/Last Update: 2019-10-12